Pharmas’ payments to doctors raise concerns about prescription bias and have triggered bribery investigations, too. So, to win patients’ trust, transparency matters. And now, AstraZeneca is going beyond its Big Pharma fellows to disclose all its doc payments, even in regions where it’s not required. CEO Pascal Soriot told investors at its annual meeting that his company plans to disclose payments in all countries where it has commercial activities, according to The Times. Several countries, including the U.S., require those disclosures under local regulations. “There was no reason for us not to disclose,” said Soriot, as quoted by The Times of London. “It’s only a …
juin, 2018
-
12 juin
Infraction à la loi “anti-cadeaux” : la Cour de cassation confirme l’arrêt de la cour d’appel de Paris ayant prononcé l’an dernier des amendes records
English version below Olivier Lantrès et Sébastien Pradeau du cabinet fieldfisher nous signalent que a Cour de cassation vient de confirmer, dans un arrêt très sévère, la décision de la cour d’appel de Paris ayant prononcé des amendes d’un montant record le 29 mars 2017, à l’encontre d’entreprises de santé, intervenant dans le domaine dentaire, et de leur mandataire social (75.000 € d’amende pour ce dernier). Tous les prévenus avaient formé un pourvoi contre l’arrêt de la cour d’appel. Il est rare que la Cour de cassation se prononce sur l’application de la loi “anti-cadeaux” et cet arrêt est amené, …
mai, 2018
-
25 mai
Bipartisan Trio of Senators Introduces New Open Payments Transparency Bill
Senator Chuck Grassley, along with Senator Sherrod Brown and Senator Richard Blumenthal recently introduced bipartisan legislation that is expected to increase transparency in the prescription drug payment process, S. 2891, The “Fighting the Opioid Epidemic with Sunshine Act.” The Fighting the Opioid Epidemic with Sunshine Act will require drug companies and medical device makers to publicly disclose the same payments made to nurse practitioners and physician assistants for promotional talks, consulting, and other interactions. Nurse practitioners and physician assistants write a significant number of prescriptions and should be included in these disclosures. The Senators believe that “by shining a light on the …
-
25 mai
Prévention des conflits d’intérêts : l’AP-HP et le SNITEM signent une convention cadre des visites médicales
L’AP-HP a signé le 18 avril 2018, avec le Syndicat national de l’industrie des technologies médicales (SNITEM), une convention visant à encadrer les activités promotionnelles, au sein de ses 39 hôpitaux, d’agents commerciaux agissant au nom d’entreprises qui produisent et commercialisent des dispositifs médicaux. Cette convention cadre précise les conditions dans lesquelles les représentants des entreprises adhérentes au SNITEM accèdent aux hôpitaux dans la perspective de faire connaître et promouvoir des produits auprès des professionnels de santé. Elle fait partie des mesures prises par l’AP-HP depuis 2015 pour mieux prévenir les conflits d’intérêts dans ses hôpitaux*. La convention cadre signée …
avril, 2018
-
24 avril
Compliance & Life Sciences in Europe, what’s new?
How to deal with the main principles governing transparency and anti-kickback? A conference hosted by Fieldfisher in partnership with Pharmaceutiques.
-
6 avril
Comparing Transparency Reporting Requirements in Canada, the United States and Europe
The Strengthening Quality and Accountability for Patients Act 2017 (the “Transparency Act”) was passed in December 2017 and requires the reporting of transfers of value (“TOV”) from manufacturers (e.g., pharmaceutical, medical device, generics, medicinal marijuana, etc.), pharmacies, laboratories, organizers of continuing education events and “a prescribed person or entity” to prescribed recipients in Ontario. Like the U.S. Sunshine Act and the EFPIA reporting requirements, the Transparency Act was created with the goal of strengthening transparency by requiring companies to track and report certain payments and items of value. However, the reporting requirements under the Act are still somewhat unclear and …
